Skip to main content
Bloomberg Law

How Life Sciences Firms Can Reduce DOJ Enforcement Risks

May 6, 2021
Authors
Jaime L.M. JonesJack W. Pirozzolo

The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.

View Article

Contacts

Jones, Jaime L.M.
Partner
Pirozzolo, Jack W.
Partner

Related Blogs

Capabilities

Suggested News & Insights

First Circuit Clarifies Application of Medicare’s “Reasonable and Necessary” Standard in FCA Cases Against Clinical LabsDecember 8, 2025
Original Source
Sidley Secures Landmark FCA Defense Victory for Novo NordiskNovember 18, 2025
Announcements
U.S. DOJ Announces Renewal of FCA Working GroupNovember - December 2025
Journal of Healthcare Compliance
U.S. Treasury Launches Departmentwide Review of Preference-Based Contracting ProgramsNovember 11, 2025
White Collar Defense and Investigations Update
Torrey Cope Featured on Fierce Biotech's The Top Line Podcast Episode, "Unpacking the FDA Transparency Push on CRLs"October 17, 2025
Fierce Biotech
DOJ Announces Renewal of FCA Working GroupOctober 2025
Pratt’s Government Contracting Law Report